Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XB010

Antibody-drug conjugate · Cytotoxic, directed at 5T4 oncofetal antigen (TPBG) · developed by Exelixis

Phase 1 Most advanced trial
EXEL Developer
1 Registered trials

What is XB010?

XB010 is an antibody-drug conjugate in which an anti-5T4 monoclonal antibody is linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). The antibody binds the 5T4 transmembrane glycoprotein on tumor cells, and after internalization MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis. It is being studied in solid tumors, esophageal squamous cell cancer, head and neck squamous cell cancer, non-small cell lung cancer, and breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
5T4 oncofetal antigen (TPBG), tubulin (secondary target)
Mechanism
Cytotoxic, directed at 5T4 oncofetal antigen (TPBG)
Pathways
microtubule polymerization inhibition, G2/M cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Exelixis (EXEL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06545331 Phase 1 Locally Advanced or Metastatic Solid Tumors Recruiting EXEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Esophageal Squamous Cell CancerHead and Neck Squamous Cell CancerHormone-receptor-positive Breast CancerLocally Advanced or Metastatic Solid TumorsNSCLC (Non-small Cell Lung Cancer)Triple Negative Breast Cancer (TNBC)

Other drugs acting on TPBG

More from Exelixis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EXEL page.

Follow EXEL, the company behind XB010

See EXEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EXEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.